Madrigal Pharmaceuticals Inc   (MDGL)
Other Ticker:  
Price: $251.6300 $15.43 6.533%
Day's High: $252.5 Week Perf: 8.2 %
Day's Low: $ 237.33 30 Day Perf: 16.11 %
Volume (M): 459 52 Wk High: $ 322.67
Volume (M$): $ 115,574 52 Wk Avg: $216.23
Open: $237.38 52 Wk Low: $119.76

 Market Capitalization (Millions $) 4,703
 Shares Outstanding (Millions) 19
 Employees 36
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -374
 Cash Flow (TTM) (Millions $) -232
 Capital Exp. (TTM) (Millions $) 1

Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for the treatment of serious diseases that are impacting the lives of patients around the world. The company was founded in 2011 with the goal of using its expertise in the field of liver metabolism to develop novel drugs that can help patients with various forms of liver and cardiovascular diseases.

The company's flagship product is MGL-3196, which is a selective thyroid hormone receptor beta agonist that is designed to help patients suffering from non-alcoholic steatohepatitis (NASH), a serious liver disease that is characterized by inflammation and the accumulation of fat in the liver. The drug has shown significant promise in early clinical trials, and it is currently being evaluated in phase 3 clinical trials for the treatment of NASH.

Madrigal is also developing other products that are designed to address other liver and cardiovascular diseases. One of the company's other products is MGL-3745, which is a selective thyroid hormone receptor beta agonist that is designed to help patients suffering from dyslipidemia. Dyslipidemia is a condition that is characterized by high levels of cholesterol and triglycerides in the blood, which can lead to serious health problems such as heart disease and stroke.

In addition to its drug development efforts, Madrigal is also actively engaged in research and development activities aimed at discovering new and innovative therapies for other serious diseases. The company has a team of experienced researchers and scientists who are working to identify new drug targets and develop new drug candidates that can help patients suffering from a range of diseases.

Overall, Madrigal Pharmaceuticals Inc. is a highly innovative and promising biopharmaceutical company that is focused on developing new and effective treatments for serious diseases. With its focus on liver and cardiovascular diseases and its highly experienced team of researchers and scientists, the company is well-positioned to make a significant impact on the lives of patients around the world.

   Company Address: Four Tower Bridge West Conshohocken 19428 PA
   Company Phone Number: 824-2827   Stock Exchange / Ticker: NASDAQ MDGL


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc Faces Decline in Shares, Operating Loss in Fourth Quarter of 2023

Madrigal Pharmaceuticals Inc, a clinical-stage biopharmaceutical company focused on developing therapeutics for nonalcoholic steatohepatitis (NASH), has experienced a decline in its shares in February 2024. The shares dropped by 6.44% so far this month, and by 14.36% compared to the same period last year. Despite this, Madrigal Pharmaceuticals Inc shares are currently trading on the NASDAQ at 9.1% above its 52-week average.
In the recent months, shareholders did not anticipate any changes to the company's top-line revenue during the October to December 2023 reporting cycle. However, they closely monitored the operating loss of Madrigal Pharmaceuticals Inc, which amounted to $-117.176 million during the same period. It is worth noting that the company has not yet declared its revenue, but to better understand its recent efforts, we can compare it to the operating loss of $-85.299 million in the fourth quarter of 2022.

Clinical Study

Resmetirom Shows Promising Results in Phase 3 Trial for NASH Treatment, Published in New England Journal of Medicine

Published Thu, Feb 8 2024 1:01 PM UTC

Madrigal Pharmaceuticals Announces Promising Results for Resmetirom in Phase 3 Trial for NASH TreatmentCONSHOHOCKEN, Pa., Feb. 08, 2024 - Madrigal Pharmaceuticals, a leading clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for nonalcoholic steatohepatitis (NASH), has recently announced the publication of the pivotal Phase 3 MAESTRO-NAS...


Madrigal Pharmaceuticals Increases Workforce and Expands Inducement Plan

Published Tue, Feb 6 2024 9:05 PM UTC

In an official press release today, Madrigal Pharmaceuticals, a renowned clinical-stage biopharmaceutical company focusing on groundbreaking therapies for nonalcoholic steatohepatitis (NASH), announced the issuance of equity awards to seven new employees. This move comes as part of the company's commitment to strengthening its workforce and expanding its inducement...

Management Changes

Madrigal Pharmaceuticals Announces New Leadership Team Amidst Challenging Financial Quarter

Published Mon, Jan 29 2024 1:00 PM UTC

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has recently welcomed three key additions to its leadership team, aiming to bolster its pursuit of innovative therapeutics for nonalcoholic steatohepatitis (NASH). The company's latest hires include Mark Barrett as Chief Business Officer, Clint Wallace as Chief Human Resources Officer, and Tina Ventura as Chief Investor Relat...

Clinical Study

Madrigal Pharmaceuticals Promotes Cost-Effective and Patient-Centric Approaches in NASH Treatment through Health Economics Research at NASH-TAG Conference

Published Thu, Jan 4 2024 1:00 PM UTC

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual ConferenceCONSHOHOCKEN, Pa., Jan. 04, 2024 - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutics for nonalcoholic steatohepatitis (NASH), has disclosed the presentation of fi...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com